A TV interview with our CEO Jason Loveridge. Jason Loveridge discusses how 4SC AG is creating a new treatment paradigm for #CutaneousTCellLymphoma (CTCL), a rare type of non-Hodgkin lymphoma that affects the skin.
A TV interview with our CEO Jason Loveridge. Jason Loveridge discusses how 4SC AG is creating a new treatment paradigm for #CutaneousTCellLymphoma (CTCL), a rare type of non-Hodgkin lymphoma that affects the skin.